搜索医生

Parminder Singh, M.D.

  1. Hematologist
  2. Internist
  3. Oncologist
预约门诊

出版物

  1. Apolo AB, Ballman KV, Sonpavde G, Berg S, Kim WY, Parikh R, Teo MY, Sweis RF, Geynisman DM, Grivas P, Chatta G, Reichert ZR, Kim JW, Bilen MA, McGregor B, Singh P, Tripathi A, Cole S, Simon N, Niglio S, Ley L, Cordes L, Srinivas S, Huang J, Odegaard M, Watt C, Petrylak D, Hoffman-Censits J, Wen Y, Hahn O, Mitchell C, Tan A, Streicher H, Sharon E, Moon H, Woods M, Halabi S, Perez Burbano G, Morris MJ, Rosenberg JE. Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2024 Sep 15 Epub 2024 Sept 15
    View PubMed
  2. Shah VS, Irvine C, McWilliams RR, Singh P, Soefje SA. Reducing Cancer Drug Cost: 3-Year Analysis of Automated Dose Rounding in Electronic Health Records. JCO Oncol Pract. 2024 Aug 5; OP2300688 Epub 2024 Aug 05
    View PubMed
  3. Singh KP, Cooper BA, Paul SM, Ruddy K, Singh AB, Chen J, Pituch KA, Grys TE, Singh P, Batalini F, Hammer MJ, Levine JD, Miaskowski C. Gastrointestinal and Neuropsychological Symptoms Are Associated With Distinct Vomiting Profiles in Patients Receiving Chemotherapy. Oncol Nurs Forum. 2024 Jun 14; 51 (4):361-380
    View PubMed
  4. Moussa MJ, Khandelwal J, Wilson NR, Naik SA, Subbiah V, Campbell MT, Msaouel P, Singh P, Alhalabi O. Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy. Curr Oncol. 2024 Jun 13; 31 (6):3342-3349 Epub 2024 June 13
    View PubMed
  5. Toesca DAS, Cheney SM, Singh P, Stanton ML, Wong WW. On Complete Clinical Response of Basal Cell Carcinoma of the Prostate After Definitive Concurrent Chemoradiation. Adv Radiat Oncol. 2024 Apr; 9 (4):101427 Epub 2023 Dec 23
    View PubMed
  6. Singh P, Ballas L, Sonpavde GP, Chen RC, Bangs R, Bauman BC, Nagar H, Delacroix SE, Lerner SP, Efstathiou JA. Eligibility and Endpoints for Clinical Trials in Trimodality Therapy for Bladder Cancer. Bladder Cancer. 2024; 10 (3):199-213 Epub 2024 Oct 23
    View PubMed
  7. Black PC, Tangen CM, Singh P, McConkey DJ, Lucia MS, Lowrance WT, Koshkin VS, Stratton KL, Bivalacqua TJ, Kassouf W, Porten SP, Bangs R, Plets M, Thompson IM Jr, Lerner SP. Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guerin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605. Eur Urol. 2023 Dec; 84 (6):536-544 Epub 2023 Aug 16
    View PubMed
  8. Ng CT, Bonilla HMG, Bryce AH, Singh P, Herrmann J. Approaches to Prevent and Manage Cardiovascular Disease in Patients Receiving Therapy for Prostate Cancer. Curr Cardiol Rep. 2023 Aug; 25 (8):889-899 Epub 2023 July 25
    View PubMed
  9. El Zarif T, Nassar AH, Adib E, Fitzgerald BG, Huang J, Mouhieddine TH, Rubinstein PG, Nonato T, McKay RR, Li M, Mittra A, Owen DH, Baiocchi RA, Lorentsen M, Dittus C, Dizman N, Falohun A, Abdel-Wahab N, Diab A, Bankapur A, Reed A, Kim C, Arora A, Shah NJ, El-Am E, Kozaily E, Abdallah W, Al-Hader A, Abu Ghazal B, Saeed A, Drolen C, Lechner MG, Drakaki A, Baena J, Nebhan CA, Haykal T, Morse MA, Cortellini A, Pinato DJ, Dalla Pria A, Hall E, Bakalov V, Bahary N, Rajkumar A, Mangla A, Shah V, Singh P, Aboubakar Nana F, Lopetegui-Lia N, Dima D, Dobbs RW, Funchain P, Saleem R, Woodford R, Long GV, Menzies AM, Genova C, Barletta G, Puri S, Florou V, Idossa D, Saponara M, Queirolo P, Lamberti G, Addeo A, Bersanelli M, Freeman D, Xie W, Reid EG, Chiao EY, Sharon E, Johnson DB, Ramaswami R, Bower M, Emu B, Marron TU, Choueiri TK, Baden LR, Lurain K, Sonpavde GP, Naqash AR. Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium. J Clin Oncol. 2023 Jul 20; 41 (21):3712-3723 Epub 2023 May 16
    View PubMed
  10. Singh KP, Cooper BA, Tofthagen CS, Fryer JD, Singh P, Pituch K, Zhu Q, Gu H, Hammer MJ, Conley YP, Levine JD, Miaskowski C. Higher Levels of Stress and Neuropsychological Symptoms Are Associated With a High Nausea Profile in Patients With Cancer Receiving Chemotherapy. Oncol Nurs Forum. 2023 Jun 15; 50 (4):461-473
    View PubMed
  11. Riaz IB, Naqvi SAA, He H, Asghar N, Siddiqi R, Liu H, Singh P, Childs DS, Ravi P, Hussain SA, Murad MH, Boorjian SA, Sweeney C, Van Allen EM, Bryce AH. First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer: A Living Systematic Review and Network Meta-analysis. JAMA Oncol. 2023 May 1; 9 (5):635-645
    View PubMed
  12. Chesney JA, Puzanov I, Collichio FA, Singh P, Milhem MM, Glaspy J, Hamid O, Ross M, Friedlander P, Garbe C, Logan T, Hauschild A, Lebbe C, Joshi H, Snyder W, Mehnert JM. Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial. J Immunother Cancer. 2023 May; 11 (5)
    View PubMed
  13. Sarkar S, Min K, Ikram W, Tatton RW, Riaz IB, Silva AC, Bryce AH, Moore C, Ho TH, Sonpavde G, Abdul-Muhsin HM, Singh P, Wu T. Performing Automatic Identification and Staging of Urothelial Carcinoma in Bladder Cancer Patients Using a Hybrid Deep-Machine Learning Approach. Cancers (Basel). 2023 Mar 8; 15 (6) Epub 2023 Mar 08
    View PubMed
  14. Riaz IB, Islam M, Ikram W, Naqvi SAA, Maqsood H, Saleem Y, Riaz A, Ravi P, Wang Z, Hussain SA, Warner JL, Odedina FT, Duma N, Singh P, Kehl KL, Kamran SC, Murad MH, Landman A, Van Allen E, Bryce AH. Disparities in the Inclusion of Racial and Ethnic Minority Groups and Older Adults in Prostate Cancer Clinical Trials: A Meta-analysis. JAMA Oncol. 2023 Feb 1; 9 (2):180-187
    View PubMed
  15. Ballas L, Singh P, Lerner SP. Targeting barriers to wider use of trimodality therapy in localized muscle invasive bladder cancer. Urol Oncol. 2023 Jan; 41 (1):35-38 Epub 2020 Nov 03
    View PubMed
  16. Girardi DM, Ghatalia P, Singh P, Iyer G, Sridhar SS, Apolo AB. Systemic therapy in bladder preservation. Urol Oncol. 2023 Jan; 41 (1):39-47 Epub 2020 Nov 19
    View PubMed
  17. Park H, Shapiro GI, Gao X, Mahipal A, Starr J, Furqan M, Singh P, Ahrorov A, Gandhi L, Ghosh A, Hickman D, Gallacher PD, Wennborg A, Attar EC, Awad MM, Das S, Dumbrava EE. Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors. ESMO Open. 2022 Oct; 7 (5):100573 Epub 2022 Sept 07
    View PubMed
  18. Liu AJ, Kosiorek HE, Ueberroth BE, Jaeger E, Ledet E, Kendi AT, Tzou K, Quevedo F, Choo R, Moore CN, Ho TH, Singh P, Keole SR, Wong WW, Sartor O, Bryce AH. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases. Prostate. 2022 Sep; 82(12):1202-1209. Epub 2022 Jun 02.
    View PubMed
  19. Velez MG, Kosiorek HE, Egan JB, McNatty AL, Riaz IB, Hwang SR, Stewart GA, Ho TH, Moore CN, Singh P, Sharpsten RK, Costello BA, Bryce AH. Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 2022 Sep; 25 (3):479-483 Epub 2021 July 22
    View PubMed
  20. Riaz IB, Islam M, Khan AM, Naqvi SAA, Siddiqi R, Khakwani KZR, Asghar N, Ikram W, Hussain SA, Singh P, Warner JL, Sonpavde GP, Odedina FT, Kehl KL, Duma N, Bryce AH. Disparities in Representation of Women, Older Adults, and Racial/Ethnic Minorities in Immune Checkpoint Inhibitor Trials. Am J Med. 2022 Aug; 135 (8):984-992.e6 Epub 2022 Apr 25
    View PubMed
  21. Agarwal N, McGregor B, Maughan BL, Dorff TB, Kelly W, Fang B, McKay RR, Singh P, Pagliaro L, Dreicer R, Srinivas S, Loriot Y, Vaishampayan U, Goel S, Curran D, Panneerselvam A, Schwickart M, Choueiri TK, Pal S. Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). Lancet Oncol. 2022 Jul; 23 (7):899-909 Epub 2022 June 09
    View PubMed
  22. Riaz IB, Sipra QUAR, Naqvi SAA, He H, Siddiqi R, Islam M, Asghar N, Ikram W, Xu W, Liu H, Singh P, Ho TH, Bilen MA, Zakharia Y, Bryce AH, Murad MH. Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis. Crit Rev Oncol Hematol. 2022 Jul; 175:103706. Epub 2022 May 07.
    View PubMed
  23. Riaz IB, He H, Ryu AJ, Siddiqi R, Naqvi SAA, Yao Y, Husnain M, Narasimhulu DM, Mathew J, Sipra QUAR, Vandvik PO, Joseph RW, Liu H, Wang Z, Herasevich V, Singh P, Hussain SA, Ho TH, Bryce AH, Pagliaro LC, Murad MH, Costello BA. A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma. Eur Urol. 2021 Dec; 80 (6):712-723 Epub 2021 Apr 03
    View PubMed
  24. Ravi P, Pond GR, Diamantopoulos LN, Su C, Alva A, Jain RK, Skelton WP 4th, Gupta S, Tward JD, Olson KM, Singh P, Grunewald CM, Niegisch G, Lee JL, Gallina A, Bandini M, Necchi A, Mossanen M, McGregor BA, Curran C, Grivas P, Sonpavde GP. Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration. BJU Int. 2021 Nov; 128 (5):607-614 Epub 2021 May 18
    View PubMed
  25. Nafissi NN, Kosiorek HE, Butterfield RJ, Moore C, Ho T, Singh P, Bryce AH. Evolving Natural History of Metastatic Prostate Cancer. Cureus. 2020 Nov 14; 12 (11):e11484
    View PubMed
  26. Kekic A, Seetharam M, Singh P, Kunze K, Golafshar M, Azevedo C, Welp S, Bofferding A, Koep T, Ross J, Nelson E, Grilli C, Samadder J. Integrating pharmacogenomics panel testing for supportive care medications in patients with solid tumors. Journal of Clinical Oncology. 2020 May; 38(Suppl 15):e24114-e24114.
  27. Petrylak DP, Vogelzang NJ, Chatta K, Fleming MT, Smith DC, Appleman LJ, Hussain A, Modiano M, Singh P, Tagawa ST, Gore I, McClay EF, Mega AE, Sartor AO, Somer B, Wadlow R, Shore ND, Olson WC, Stambler N, DiPippo VA, Israel RJ. PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study. Prostate. 2020 Jan; 80 (1):99-108 Epub 2019 Nov 19
    View PubMed
  28. Chesney J, Puzanov I, Collichio F, Milhem MM, Hauschild A, Chen L, Sharma A, Garbe C, Singh P, Mehnert JM. Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma. Br J Cancer. 2019 Aug; 121 (5):417-420 Epub 2019 July 29
    View PubMed
  29. Bin Riaz I, Umar M, Zahid U, Husnain M, Iftikhar A, McBride A, Bilal J, Javed A, Akbar S, Singh P, Ali Z, Sipra QUAR, Gondal FR, Ahman F, Anwer F. Role of one, two and three doses of high-dose chemotherapy with autologous transplantation in the treatment of high-risk or relapsed testicular cancer: a systematic review. Bone Marrow Transplant. 2018 Oct; 53 (10):1242-1254 Epub 2018 Apr 27
    View PubMed
  30. Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J, Hamid O, Ross M, Friedlander P, Garbe C, Logan TF, Hauschild A, Lebbe C, Chen L, Kim JJ, Gansert J, Andtbacka RHI, Kaufman HL. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. J Clin Oncol. 2018 Jun 10; 36 (17):1658-1667 Epub 2017 Oct 05
    View PubMed
  31. Singh P, Black P. Emerging role of checkpoint inhibition in localized bladder cancer. Urol Oncol. 2016 Dec; 34 (12):548-555 Epub 2016 Oct 21
    View PubMed
  32. Harryman WL, Hinton JP, Rubenstein CP, Singh P, Nagle RB, Parker SJ, Knudsen BS, Cress AE. The Cohesive Metastasis Phenotype in Human Prostate Cancer. Biochim Biophys Acta. 2016 Dec; 1866 (2):221-231 Epub 2016 Sept 24
    View PubMed
  33. Harryman WL, Pond E, Singh P, Little AS, Eschbacher JM, Nagle RB, Cress AE. Laminin-binding integrin gene copy number alterations in distinct epithelial-type cancers. Am J Transl Res. 2016; 8 (2):940-54 Epub 2016 Feb 15
    View PubMed
  34. Pal SK, Singh P, Vogelzang NJ. PD-1/PD-L1 in Renal Cell Carcinoma: Projecting the Way Forward. Clin Genitourin Cancer. 2015 Aug; 13 (4):257-60 Epub 2014 July 14
    View PubMed
  35. Necchi A, Pond GR, Giannatempo P, Di Lorenzo G, Eigl BJ, Locke J, Pal SK, Agarwal N, Poole A, Vaishampayan UN, Niegisch G, Hussain SA, Singh P, Bellmunt J, Sonpavde G. Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy. Clin Genitourin Cancer. 2015 Apr; 13 (2):178-84 Epub 2014 Sept 23
    View PubMed
  36. Singh P, Pal SK, Alex A, Agarwal N. Development of PROSTVAC immunotherapy in prostate cancer. Future Oncol. 2015; 11 (15):2137-48
    View PubMed
  37. Singh P, Agarwal N, Pal SK. Sequencing systemic therapies for metastatic kidney cancer. Curr Treat Options Oncol. 2015 Jan; 16 (1):316
    View PubMed
  38. Algotar AM, Behnejad R, Singh P, Thompson PA, Hsu CH, Stratton SP. EFFECT OF SELENIUM SUPPLEMENTATION ON PROTEOMIC SERUM BIOMARKERS IN ELDERLY MEN. J Frailty Aging. 2015; 4 (2):107-10
    View PubMed
  39. Algotar AM, Hsu CH, Singh P, Stratton SP. Selenium supplementation has no effect on serum glucose levels in men at high risk of prostate cancer. J Diabetes. 2013 Dec; 5 (4):465-70 Epub 2013 May 29
    View PubMed
  40. Singh P, Algotar AM, Bracamonte ER. Prostatic small cell carcinoma: Diagnosis and management. Journal of Cancer Therapy.2013;4:804-10.
  41. Singh P, Kaur H, Lerner RG, Patel R, Rafiyath SM, Singh Lamba G. Hepatocellular carcinoma in non-cirrhotic liver without evidence of iron overload in a patient with primary hemochromatosis. Review. J Gastrointest Cancer. 2012 Mar; 43 (1):36-9
    View PubMed
  42. Lamba G, Rafiyath SM, Kaur H, Khan S, Singh P, Hamilton AM, Ang DC. Malignant glomus tumor of kidney: the first reported case and review of literature. Hum Pathol. 2011 Aug; 42 (8):1200-3 Epub 2011 Feb 18
    View PubMed
  43. Desai HV, Gandhi K, Sharma M, Jennine M, Singh P, Brogan M. Thiazide-induced severe hypercalcemia: a case report and review of literature. Am J Ther. 2010 Nov-Dec; 17 (6):e234-6
    View PubMed
  44. Gandhi K, Aronow WS, Desai H, Amin H, Sharma M, Lai HM, Singh P. Cardiovascular manifestations in patients with thrombotic thrombocytopenic purpura: a single-center experience. Clin Cardiol. 2010 Apr; 33 (4):213-6
    View PubMed
  45. Singh P, Aronow WS, Mellana WM, Gutwein AH. Prevalence of appropriate management of diabetes mellitus in an academic general medicine clinic. Am J Ther. 2010 Jan-Feb; 17 (1):42-5
    View PubMed
  46. Singh P, Sharma M, Gandhi K, Nelson J, Kaul A. Acute mesenteric vein thrombosis after laparoscopic gastric sleeve surgery for morbid obesity. Surg Obes Relat Dis. 2010 Jan-Feb; 6 (1):107-8 Epub 2009 Aug 19
    View PubMed
  47. Singh P, Lai HM, Lerner RG, Chugh T, Aronow WS. Guidelines and the use of inferior vena cava filters: a review of an institutional experience. J Thromb Haemost. 2009 Jan; 7 (1):65-71 Epub 2008 Oct 31
    View PubMed
  48. Pierre-Louis B, Singh P, Frishman WH. Acute inferior wall myocardial infarction and percutaneous coronary intervention of the right coronary during active labor: a clinical report and review of the literature. Cardiol Rev. 2008 Sep-Oct; 16 (5):260-8
    View PubMed
PST-20267249